VIATRIS INC. Payments of Merger Related Costs, Financing Activities
VIATRIS INC. (VTRS) reported Payments of Merger Related Costs, Financing Activities of $11.40 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities · last filed 2026-08-06
- VIATRIS INC. payments of merger related costs, financing activities for the quarter ending 2026-06-30 was $3.50M, a 105.88% increase year-over-year.
- VIATRIS INC. payments of merger related costs, financing activities for the quarter ending 2026-03-31 was $7.90M, a 30.70% decline year-over-year.
- VIATRIS INC. payments of merger related costs, financing activities for the quarter ending 2025-12-31 was $0.00.
- VIATRIS INC. payments of merger related costs, financing activities for the quarter ending 2025-09-30 was $0.00.
- VIATRIS INC. payments of merger related costs, financing activities for fiscal 2025 was $13.10M, a 58.41% decline from fiscal 2024.
- VIATRIS INC. payments of merger related costs, financing activities for fiscal 2024 was $31.50M, a 275.00% increase from fiscal 2023.
- VIATRIS INC. payments of merger related costs, financing activities for fiscal 2023 was $8.40M, a 55.56% decline from fiscal 2022.
- VIATRIS INC. payments of merger related costs, financing activities for fiscal 2022 was $18.90M, a 33.92% decline from fiscal 2021.
| Period end | Payments of Merger Related Costs, Financing Activities 3 month | Payments of Merger Related Costs, Financing Activities 6 month | Payments of Merger Related Costs, Financing Activities 9 month | Payments of Merger Related Costs, Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $11.40M 10-Q · filed 2026-08-06 | $11.40M derived: sum of 3 quarters · filed 2026-08-06 | $11.40M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $7.90M 10-Q · filed 2026-05-07 | $7.90M derived: sum of 2 quarters · filed 2026-05-07 | $7.90M derived: sum of 3 quarters · filed 2026-05-07 | $9.60M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $1.70M derived: sum of 3 quarters · filed 2026-08-06 | $13.10M 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.70M derived: sum of 2 quarters · filed 2026-08-06 | $13.10M 10-Q · filed 2025-11-06 | $13.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $13.10M 10-Q · filed 2026-08-06 | $13.10M derived: sum of 3 quarters · filed 2026-08-06 | $13.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $11.40M 10-Q · filed 2026-05-07 | $11.40M derived: sum of 2 quarters · filed 2026-05-07 | $11.40M derived: sum of 3 quarters · filed 2026-05-07 | $32.00M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $20.60M derived: sum of 3 quarters · filed 2026-02-26 | $31.50M 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $20.60M derived: sum of 2 quarters · filed 2025-11-06 | $31.50M 10-Q · filed 2025-11-06 | $31.50M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $20.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $31.50M 10-Q · filed 2025-08-07 | $31.50M derived: sum of 3 quarters · filed 2026-02-26 | $31.50M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $10.90M 10-Q · filed 2025-05-08 | $10.90M derived: sum of 2 quarters · filed 2026-02-26 | $10.90M derived: sum of 3 quarters · filed 2026-02-26 | $10.90M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $8.40M 10-K · filed 2026-02-26 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $8.40M 10-Q · filed 2024-11-07 | $8.40M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $8.40M 10-Q · filed 2024-08-08 | $8.40M derived: sum of 3 quarters · filed 2025-02-27 | $8.40M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $8.40M 10-Q · filed 2024-05-09 | $8.40M derived: sum of 2 quarters · filed 2025-02-27 | $8.40M derived: sum of 3 quarters · filed 2025-02-27 | $11.80M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | $3.40M derived: sum of 3 quarters · filed 2025-02-27 | $18.90M 10-K · filed 2025-02-27 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $3.40M derived: sum of 2 quarters · filed 2023-11-08 | $18.90M 10-Q · filed 2023-11-08 | $18.90M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $3.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $18.90M 10-Q · filed 2023-08-07 | $18.90M derived: sum of 3 quarters · filed 2024-02-28 | $18.90M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $15.50M 10-Q · filed 2023-05-08 | $15.50M derived: sum of 2 quarters · filed 2024-02-28 | $15.50M derived: sum of 3 quarters · filed 2024-02-28 | $18.10M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $0.00 derived: sum of 2 quarters · filed 2024-02-28 | $2.60M derived: sum of 3 quarters · filed 2024-02-28 | $28.60M 10-K · filed 2024-02-28 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $2.60M derived: sum of 2 quarters · filed 2022-11-07 | $28.60M 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $2.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $28.60M 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $26.00M 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | $48.50M 10-K · filed 2023-02-27 | |||
| 2020-03-31 | $19.30M 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $60.30M 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $11.90M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |